Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02968420
Other study ID # H16-00700
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 11, 2017
Est. completion date May 15, 2019

Study information

Verified date June 2021
Source University of British Columbia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall aim of this study is to further understand the memory response to HPV vaccination in subjects who have received 2 versus 3 doses of quadrivalent HPV vaccine. Although memory responses can be detected shortly after immunization, the best approach to measure the long-lasting anamnestic response is to challenge with a booster dose years (> 5) after the original exposure.


Description:

This is a single center, interventional study to evaluate long term memory response to Q-HPV vaccination and to natural infection. Memory response will be assessed by measuring seroprotection 8-10 years post Q-HPV vaccination and to challenge with a booster dose years after the original exposure to measure the long-lasting anamnestic response.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date May 15, 2019
Est. primary completion date May 15, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 17 Years to 35 Years
Eligibility Inclusion Criteria: - Written informed consent provided by the participant. - Participant whom the investigator believes can and will comply with the requirements of the protocol. - General good health. - Immunized with Q-HPV vaccine between the ages of 9-13 or 16 to 26 years on the BCGov01 study or the BC provincial program. - Participant who is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study. Examples of effective methods of birth control include: - Abstinence (no sexual activity) - Hormonal contraceptives including oral, injectable, implants & skin patches - Intrauterine device (IUD) - Male partner sterilization - Male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository) - Male condom combined with a female diaphragm, whether with or without a vaginal spermicide (foam, gel, cream, or suppository) - Adequate contraception does not apply to participants with same sex partners, when this is their preferred and usual lifestyle Exclusion Criteria: - Received more than 3 doses of Q-HPV vaccine - Received any doses of HPV9 vaccine - Systemic hypersensitivity to Q-HPV vaccine or HPV9 vaccine or severe reaction to any previous dose of Q-HPV vaccine. - Receipt of blood or blood product within 3 months prior to Visit 1. - Receipt of a live vaccine within 28 days or an inactive vaccine within 14 days of Visit 1 - Immune compromise resulting from disease or immunosuppressive systemic medication use within 3 months prior to Visit 1. - Inadequate participant fluency in English to provide fully informed consent. - Participant who is currently pregnant or planning a pregnancy during the course of the trial

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Human Papillomavirus 9-valent Vaccine, Recombinant
All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.

Locations

Country Name City State
Canada Vaccine Evaluation Center, BC Children's Hospital Research Institute Vancouver British Columbia

Sponsors (2)

Lead Sponsor Collaborator
University of British Columbia Merck Canada Inc.

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007 Jun 21;25(26):4931-9. Epub 2007 Apr 20. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary B Memory Cell Response (% of Memory B Cells That Are Antigen-specific) To compare the B memory cell populations between girls that received either a primary 2 or 3 dose series, who are then challenged with a subsequent dose after 120 months At Day 30 post challenge dose of Human Papillomavirus 9-Valent vaccine
Primary Plasmablast Response (% of All B Cells That Are Plasmablasts) To compare the plasmablast populations between girls that received either a primary 2 or 3 dose series, who are then challenged with a subsequent dose after 120 months At Day 7 post challenge dose of Human Papillomavirus 9-Valent vaccine
Secondary Variable Gene Usage (Comparison of the Nucleotide Sequences of Antigen-specific Antibody Heavy and Light Chain Variable Region Sequences) To compare the extent of somatic hypermutation and the variable gene usage between girls that received either a primary 2 or 3 dose series At Day 7 and Day 30 post challenge dose of Human Papillomavirus 9-Valent vaccine
Secondary Serum Antibody Response (cLIA) - Geometric Mean Titer To compare the serum antibody responses (cLIA) to HPV 6, 11, 16 & 18 at month 120 in females that received either a primary 2 or 3 dose series, who are then challenged with a subsequent dose At Day 7 post challenge dose of Human Papillomavirus 9-Valent vaccine
Secondary Serum Antibody Response (cLIA) - Geometric Mean Titer To compare the serum antibody responses (cLIA) to HPV 6, 11, 16 & 18 at month 120 in females that received either a primary 2 or 3 dose series, who are then challenged with a subsequent dose At Day 30 post challenge dose of Human Papillomavirus 9-Valent vaccine
Secondary Serum Antibody Response (Total IgG) - Geometric Mean Titer To compare the serum antibody responses (total IgG) to HPV 6, 11, 16 & 18 at month 120 in females that received either a primary 2 or 3 dose series, who are then challenged with a subsequent dose At Day 7 post challenge dose of Human Papillomavirus 9-Valent vaccine
Secondary Serum Antibody Response (Total IgG) - Geometric Mean Titer To compare the serum antibody responses (total IgG) to HPV 6, 11, 16 & 18 at month 120 in females that received either a primary 2 or 3 dose series, who are then challenged with a subsequent dose At Day 30 post challenge dose of Human Papillomavirus 9-Valent vaccine
See also
  Status Clinical Trial Phase
Completed NCT02740790 - Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females Phase 2
Completed NCT01845779 - Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal N/A
Completed NCT01422356 - Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men N/A
Completed NCT01159834 - Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital) N/A
Completed NCT02808832 - An HPV Vaccine Provider Intervention in Safety Net Clinics N/A
Completed NCT01456715 - Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later. Phase 3
Completed NCT02007421 - Study of the Prevention of Anal Cancer N/A
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Completed NCT02267876 - Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens
Recruiting NCT01459289 - Psychosocial Effect of HPV Positivity N/A
Completed NCT01358097 - Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy N/A
Completed NCT01342978 - Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time N/A
Not yet recruiting NCT06434337 - Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
Active, not recruiting NCT02576561 - Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL Phase 2
Terminated NCT02503111 - The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men N/A
Recruiting NCT02126189 - The Princess Alexandra Hospital and the QIMR Berghofer Medical Research Institute Head and Neck Cancer Study N/A
Completed NCT01766284 - Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix N/A
Completed NCT01524003 - Chinese Cancer Prevention Study(CHICAPS) N/A
Recruiting NCT05026138 - Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
Recruiting NCT03742869 - HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma